A vision for cyclodextrin nanoparticles in drug delivery systems and pharmaceutical applications

Nanomedicine

Volumn 9, Issue 6, 2014, Pages 877-894

  Lakkakula, Jaya Raju ^a,b   Maçedo Krause, Rui Werner ^b  

^a UNIVERSITY OF JOHANNESBURG   (South Africa)

^b RHODES UNIVERSITY   (South Africa)

Author keywords

amphiphilic cyclodextrins; cancer; cyclodextrin nanoparticles; drug delivery systems; gene delivery; inclusion complex; smart polymers; supramolecular structures

Indexed keywords

ADAMANTANE; ALPHA CYCLODEXTRIN; AMPHOPHILE; ANTHRACYCLINE ANTIBIOTIC AGENT; ARTEMISININ; BETA CYCLODEXTRIN; CAMPTOTHECIN; CHITOSAN; CISPLATIN; CURCUMIN; DOCETAXEL; DOXORUBICIN; GAMMA CYCLODEXTRIN; HORMONE; LIPOSOME; MACROGOL; NANOCAPSULE; NANOCARRIER; NANOPARTICLE; NANOSPHERE; PACLITAXEL; PEPTIDE; POLYACRYLIC ACID; POLYANHYDRIDE; POLYGLACTIN; POLYMER; SMALL INTERFERING RNA; TACROLIMUS; TAMOXIFEN CITRATE; TESTOSTERONE; ANTINEOPLASTIC AGENT; CYCLODEXTRIN; DRUG; DRUG CARRIER; NUCLEIC ACID;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; COMPLEX FORMATION; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; HORMONAL THERAPY; HYDROLYSIS; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MICROENCAPSULATION; NANOENCAPSULATION; NONVIRAL GENE DELIVERY SYSTEM; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; GENE TRANSFER; HUMAN; METABOLISM; NEOPLASMS; PROCEDURES; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLODEXTRINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; NANOPARTICLES; NEOPLASMS; NUCLEIC ACIDS; PHARMACEUTICAL PREPARATIONS; POLYMERS;

EID: 84903755218     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.41     Document Type: Review

References (92)

1. Villiers A. Sur la fermentation de la fécule par laction du ferment butyrique. Compt. Rend. Acad. Sci. 112, 536-538 (1891).
2. Hirayama F, Uekama K. Cyclodextrin-based controlled drug release system. Adv. Drug. Deliv. Rev. 36(1), 125-141 (1999). (Pubitemid 29074480)
3. Wenz G. Cyclodextrins as building blocks for supramolecular structures and functional units. Angew. Chem. Int. Ed. 33(8), 803-822 (1994). (Pubitemid 24986848)
4. Zhang P, Chang-Chun L, Coleman AW, Parrot-Lopez H, Galons H. Formation of amphiphilic cyclodextrins via hydrophobic esterification at the secondary hydroxyl face. Tetrahedron Lett. 32(24), 2769-2770 (1991).
5. Lehn J-M, Sanders J. Supramolecular Chemistry: Concepts and Perspectives. VCH Weinheim, Weinheim, Germany, 154 (1995).
6. Bilensoy E, Gürkaynak O, Doǧan AL, Hincal AA. Safety and efficacy of amphiphilic β-cyclodextrin nanoparticles for paclitaxel delivery. Int. J. Pharm. 347(1), 163-170 (2008). (Pubitemid 350180328)
7. Bilensoy E, Gürkaynak O, Ertan M, Şen M, Hincal AA. Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J. Pharm. Sci. 97(4), 1519-1529 (2008).
8. Agüeros M, Ruiz-Gatón L, Vauthier C et al. Combined hydroxypropyl-β-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur. J. Pharm. Sci. 38(4), 405-413 (2009).
9. Agüeros M, Zabaleta V, Espuelas S, Campanero M, Irache J. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly (anhydride) nanoparticles. J. Control. Release 145(1), 2-8 (2010).
10. Wang X, Chen C, Huo D et al. Synthesis of β-cyclodextrin modified chitosan-poly(acrylic acid) nanoparticles and use as drug carriers. Carbohydr. Polym. 90, 361-369 (2012).
11. He H, Chen S, Zhou J et al. Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. Biomaterials. 34(21), 5344-5358 (2013).
12. Çirpanli Y, Bilensoy E, Lale Doǧan A, Çaliş S. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery Eur. J. Pharm. Biopharm. 73(1), 82-89 (2009).
13. Gaur S, Chen L, Yen T et al. Preclinical study of the cyclodextrin-polymer conjugates of camptothecin CRLX101 for the treatment of gastric cancer. Nanomedicine 8(5), 721-730 (2012).
14. Dhule SS, Penfornis P, Frazier T et al. Curcumin-loaded ?- cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine 8(4), 440-451 (2012).
15. Michel D, Chitanda JM, Balogh R et al. Design and evaluation of cyclodextrin-based delivery systems to incorporate poorly soluble curcumin analogs for the treatment of melanoma. Eur. J. Pharm. Biopharm. 81(3), 548-556 (2012).
16. Quaglia F, Ostacolo L, Mazzaglia A, Villari V, Zaccaria D, Sciortino MT. The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials 30(3), 374-382 (2009).
17. Wang J, Zong J-Y, Zhao D, Zhuo R-X, Cheng S-X. In situ formation of chitosan-cyclodextrin nanospheres for drug delivery. Colloids Surf. B Biointerfaces. 87(1), 198-202 (2011).
18. Mazzaferro S, Bouchemal K, Skanji R, Gueutin C, Chacun H, Ponchel G. Intestinal permeation enhancement of docetaxel encapsulated into methyl-β-cyclodextrin/ poly(isobutylcyanoacrylate) nanoparticles coated with thiolated chitosan. J. Control. Release 162(3), 568-574 (2012).
19. Anand R, Manoli F, Manet I et al. β-cyclodextrin polymer nanoparticles as carriers for doxorubicin and artemisinin: a spectroscopic and photophysical study. Photochem. Photobiol. Sci. 11(8), 1285-1292 (2012).
20. Memisoglu-Bilensoy E, Vural I, Bochot A, Renoir JM, Duchene D, Hincal AA. Tamoxifen citrate loaded amphiphilic β-cyclodextrin nanoparticles: in vitro characterization and cytotoxicity. J. Control. Release 104(3), 489-496 (2005). (Pubitemid 40724944)
21. Zhu W, Zhang K, Chen Y, Xi F. Simple, clean preparation method for cross-linked ?-cyclodextrin nanoparticles via inclusion complexation. Langmuir 29(20), 5939-5943 (2013).
22. Sortino S, Mazzaglia A, Mons Scolaro L, Marino Merlo F, Valveri V, Sciortino MT. Nanoparticles of cationic amphiphilic cyclodextrins entangling anionic porphyrins as carrier-sensitizer system in photodynamic cancer therapy. Biomaterials 27(23), 4256-4265 (2006).
23. Thiele C, Auerbach D, Jung G, Qiong L, Schneider M, Wenz G. Nanoparticles of anionic starch and cationic cyclodextrin derivatives for the targeted delivery of drugs. Polym. Chem. 2(1), 209-215 (2011).
24. Sahu S, Mohapatra S. Multifunctional magnetic fluorescent hybrid nanoparticles as carriers for the hydrophobic anticancer drug 5-fluorouracil. Dalton Trans. 42(6), 2224-2231 (2013).
25. Gao S, Sun J, Fu D, Zhao H, Lan M, Gao F. Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-β-cyclodextrin inclusion complex-loaded albumin nanoparticles. Int. J. Pharm. 427(2), 410-416 (2012).
26. Alamdarnejad G, Sharif A, Taranejoo S et al. Synthesis and characterization of thiolated carboxymethyl chitosan-graft-cyclodextrin nanoparticles as a drug delivery vehicle for albendazole. J. Mater. Sci. Mater. Med. 24(8), 1939-1949 (2013).
27. Bozkir A, Saka OM. Chitosan nanoparticles for plasmid DNA delivery: effect of chitosan molecular structure on formulation and release characteristics. Drug Deliv. 11(2), 107-112 (2004). (Pubitemid 38437079)
28. Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control. Release 115(2), 216-225 (2006). (Pubitemid 44559708)
29. Teijeiro-Osorio D, Remuán-López C, Alonso MJ. Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro. Eur. J. Pharm. Biopharm. 71(2), 257-263 (2009).
30. Park In-K, Recum HA. von, Jiang S, Pun SH. Supramolecular assembly of cyclodextrin-based nanoparticles on solid surfaces for gene delivery. Langmuir 22, 8478-8484 (2006). (Pubitemid 44547074)
31. Godinho B. Ogier JR, Darcy R, ODriscoll CM, Cryan JF, Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntingtons disease. Mol. Pharm. 10, 640-649 (2013).
32. Chaturvedi K, Ganguly K, Kulkarni AR, Kulkarni VH et al. Cyclodextrin-based siRNA delivery nanaocarriers: a state-of-the-art review. Expert Opin. Drug Deliv. 8, 1455-1468 (2011).
33. Ping Y, Liu C, Zhang Z, Liu KL, Chen J, Li J. Chitosan-graft-(PEI-β- cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery. Biomaterials 32(32), 8328-8341 (2011).
34. Guo J, Ogier JR, Desgranges S, Darcy R. Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials 33(31), 7775-7784 (2012).
35. OMahony AM, Ogier J, Desgranges S, Cryan JF, Darcy R, ODriscoll CM. A click chemistry route to 2-functionalised PEGylated and cationic β-cyclodextrins: co-formulation opportunities for siRNA delivery. Org. Biomol. Chem. 10(25), 4954-4960 (2012).
36. Trapani A, Lopedota A, Franco M et al. A comparative study of chitosan and chitosan/cyclodextrin nanoparticles as potential carriers for the oral delivery of small peptides. Eur. J. Pharm. Biopharm. 75(1), 26-32 (2010).
37. Méndez-Ardoy A, Urbiola K, Aranda C, Ortiz-Mellet C, García-Fernández JM, De Ilarduya CT. Polycationic amphiphilic cyclodextrin-based nanoparticles for therapeutic gene delivery. Nanomedicine (Lond.) 6(10), 1697-1707 (2011).
38. Byrne C, Sallas F, Rai DK, Ogier J, Darcy R. Poly-6-cationic amphiphilic cyclodextrins designed for gene delivery. Org. Biomol. Chem. 7(18), 3763-3771 (2009).
39. Bellocq NC, Pun SH, Jensen GS, Davis ME. Transferrin-containing, cyclodextrin polymer based particles for tumor targeted gene delivery. Bioconjugate Chem. 14, 1122-1132 (2003). (Pubitemid 37449039)
40. Cerchiara T, Luppi B, Bigucci F, Zecchi V. Effect of chitosan on progesterone release from hydroxypropyl-β-cyclodextrin complexes. Int. J. Pharm. 258(1-2), 209-215 (2003). (Pubitemid 36712884)
41. Da Silveira AM, Ponchel G, Puisieux F, Duchêne D. Combined poly(isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs. Pharm. Res. 15(7), 1051-1055 (1998). (Pubitemid 28356922)
42. Memişoǧlu E, Bochot A, Şen M, Duchêne D, Hincal AA. Non-surfactant nanospheres of progesterone inclusion complexes with amphiphilic β-cyclodextrins. Int. J. Pharm. 251(1-2), 143-153 (2003). (Pubitemid 36071469)
43. Memisoglu-Bilensoy E, Sen M, Hincal AA. Effect of drug physicochemical properties on in vitro characteristics of amphiphilic cyclodextrin nanospheres and nanocapsules. J. Microencapsul. 23(1), 59-68 (2006). (Pubitemid 43820937)
44. Cavalli R, Trotta F, Carlotti ME, Possetti B, Trotta M. Nanoparticles derived from amphiphilic γ-cyclodextrins. J. Incl. Phenom. Macrocycl. Chem. 57(1-4), 657-661 (2007).
45. Lemos-Senna E, Wouessidjewe D, Lesieur S, Duchene D. Preparation of amphiphilic cyclodextrin nanospheres using the emulsification solvent evaporation method. Influence of the surfactant on preparation and hydrophobic drug loading. Int. J. Pharm. 170(1), 119-128 (1998). (Pubitemid 28473252)
46. Zhang N, Li J, Jiang W et al. Effective protection and controlled release of insulin by cationic β-cyclodextrin polymers from alginate/chitosan nanoparticles. Int. J. Pharm. 393(1), 213-219 (2010).
47. Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int. J. Pharm. 325(1), 147-154 (2006). (Pubitemid 44573692)
48. Sajeesh S, Bouchemal K, Marsaud V, Vauthier C, Sharma CP. Cyclodextrin complexed insulin encapsulated hydrogel microparticles: an oral delivery system for insulin. J. Control. Release 147(3), 377-384 (2010).
49. Xuejiao Z, Xinge Z, Xiujun G, Shunjun S. β-cyclodextrin grafting hyperbranched polyglycerols as carriers for nasal insulin delivery. Carbohydr. Polym. 84(4), 1419-1425 (2010).
50. Zhang X, Wu Z, Gao X et al. Chitosan bearing pendant cyclodextrin as a carrier for controlled protein release. Carbohydr. Polym. 77(2), 394-401 (2009).
51. Krauland AH, Alonso MJ. Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system. Int. J. Pharm. 340(1), 134-142 (2007). (Pubitemid 47043346)
52. Cavalli R, Donalisio M, Civra A et al. Enhanced antiviral activity of acyclovir loaded into β-cyclodextrin-poly(4- acryloylmorpholine) conjugate nanoparticles. J. Control. Release 137(2), 116-122 (2009).
53. Daoud-Mahammed S, Ringard-Lefebvre C, Razzouq N et al. Spontaneous association of hydrophobized dextran and poly- β-cyclodextrin into nanoassemblies: formation and interaction with a hydrophobic drug. J. Colloid Interface Sci. 307(1), 83-93 (2007). (Pubitemid 46275703)
54. Nielsen AL, Steffensen K, Larsen KL. Self-assembling microparticles with controllable disruption properties based on cyclodextrin interactions. Colloids Surf. B Biointerfaces 73(2), 267-275 (2009).
55. Boudad H, Legrand P, Lebas G, Cheron M, Duchene D, Ponchel G. Combined hydroxypropyl-β-cyclodextrin and poly (alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int. J. Pharm. 218(1), 113-124 (2001). (Pubitemid 32406162)
56. Hwang J, Rodgers K, Oliver JC, Schluep T. α-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int. J. Nano. 3(3), 359-372 (2008).
57. Jingou J, Shilei H, Weiqi L, Danjun W, Tengfei W, Yi X. Preparation, characterization of hydrophilic and hydrophobic drug in combine loaded chitosan/cyclodextrin nanoparticles and in vitro release study. Colloids Surf. B Biointerfaces. 83(1), 103-107 (2011).
58. Trapani A, Garcia-Fuentes M, Alonso M. Novel drug nanocarriers combining hydrophilic cyclodextrins and chitosan. Nanotechnology 19(18), 185101 (2008).
59. Du Y-Z, Xu J-G, Wang L, Yuan H, Hu F-Q. Preparation and characteristics of hydroxypropyl-β-cyclodextrin polymeric nanocapsules loading nimodipine. Eur. Polym. J. 45(5), 1397-1402 (2009).
60. Sangwai M, Vavia P. Amorphous ternary cyclodextrin nanocomposites of telmisartan for oral drug delivery: Improved solubility and reduced pharmacokinetic variability. Int. J. Pharm. 453(2), 423-432 (2013).
61. Memişoǧlu E, Bochot A, Özalp M, Şen M, Duchêne D, Hincal AA. Direct formation of nanospheres from amphiphilic β-cyclodextrin inclusion complexes. Pharm. Res. 20(1), 117-125 (2003). (Pubitemid 36152926)
62. Xin J, Guo Z, Chen X, Jiang W, Li J, Li M. Study of branched cationic β-cyclodextrin polymer/indomethacin complex and its release profile from alginate hydrogel. Int. J. Pharm. 386(1), 221-228 (2010).
63. Anirudhan T, Dilu D, Sandeep S. Synthesis and characterisation of chitosan crosslinked-β-cyclodextrin grafted silylated magnetic nanoparticles for controlled release of indomethacin. J. Magn. Magn. Mater. 343, 149-156 (2013).
64. Calvo J, Lavandera JL, Agüeros M, Irache JM. Cyclodextrin/ poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone. Biomed. Microdevices 13(6), 1015-1025 (2011).
65. Sadighi A, Ostad S, Rezayat S, Foroutan M, Faramarzi M, Dorkoosh F. Mathematical modelling of the transport of hydroxypropyl-β-cyclodextrin inclusion complexes of ranitidine hydrochloride and furosemide loaded chitosan nanoparticles across a Caco-2 cell monolayer. Int. J. Pharm. 422(1), 479-488 (2012).
66. Cirri M, Bragagni M, Mennini N, Mura P. Development of a new delivery system consisting in drug-in cyclodextrin-in nanostructured lipid carriers for ketoprofen topical delivery. Eur. J. Pharm. Biopharm. 80(1), 46-53 (2012).
67. Yuan Z, Ye Y, Gao F et al. Chitosan-graft-β-cyclodextrin nanoparticles as a carrier for controlled drug release. Int. J. Pharm. 446(1-2), 191-198 (2013).
68. Banerjee SS, Chen D-H. Magnetic nanoparticles grafted with cyclodextrin for hydrophobic drug delivery. Chem. Mater. 19(25), 6345-6349 (2007).
69. Maestrelli F, Zerrouk N, Cirri M, Mennini N, Mura P. Microspheres for colonic delivery of ketoprofen- hydroxypropyl-β-cyclodextrin complex. Eur. J. Pharm. Sci. 34(1), 1-11 (2008).
70. Ghera BB, Perret F, Chevalier Y, Parrot-Lopez H. Novel nanoparticles made from amphiphilic perfluoroalkyl ?-cyclodextrin derivatives: preparation, characterization and application to the transport of acyclovir. Int. J. Pharm. 375(1), 155-162 (2009).
71. Perret F, Marminon C, Zeinyeh W et al. Preparation and characterization of CK2 inhibitor-loaded cyclodextrin nanoparticles for drug delivery. Int. J. Pharm. 441(1-2), 491-498 (2013).
72. Perret F, Duffour M, Chevalier Y, Parrot-Lopez H. Design, synthesis, and in vitro evaluation of new amphiphilic cyclodextrin-based nanoparticles for the incorporation and controlled release of acyclovir. Eur. J. Pharm. Biopharm. 83(1), 25-32 (2013).
73. Mahmoud AA, El-Feky GS, Kamel R, Awad GE. Chitosan/ sulfobutylether- β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int. J. Pharm. 413(1), 229-236 (2011).
74. Agüeros M, Areses P, Campanero MA et al. Bioadhesive properties and biodistribution of cyclodextrin-poly (anhydride) nanoparticles. Eur. J. Pharm. Sci. 37(3-4), 231-240 (2009).
75. Luppi B, Bigucci F, Corace G et al. Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur. J. Pharm. Sci. 44(4), 559-565 (2011).
76. Trapani A, Laquintana V, Denora N et al. Eudragit RS 100 microparticles containing 2-hydroxypropyl-β-cyclodextrin and glutathione: physicochemical characterization, drug release and transport studies. Eur. J. Pharm. Sci. 30(1), 64-74 (2007). (Pubitemid 44908928)
77. Lopedota A, Trapani A, Cutrignelli A et al. The use of Eudragit RS 100/cyclodextrin nanoparticles for the transmucosal administration of glutathione. Eur. J. Pharm. Biopharm. 72(3), 509-520 (2009).
78. Chaleawlert-Umpon S, Nuchuchua O, Saesoo S et al. Effect of citrate spacer on mucoadhesive properties of a novel water-soluble cationic β-cyclodextrin-conjugated chitosan. Carbohydr. Polym. 84(1), 186-194 (2011).
79. Sajomsang W, Nuchuchua O, Gonil P et al. Water-soluble β-cyclodextrin grafted with chitosan and its inclusion complex as a mucoadhesive eugenol carrier. Carbohydr. Polym. 89(2), 623-631 (2012).
80. Khalil SK, El-Feky GS, El-Banna ST, Khalil WA. Preparation and evaluation of warfarin-β-cyclodextrin loaded chitosan nanoparticles for transdermal delivery. Carbohydr. Polym. 90(3), 1244-1253 (2012).
81. Maestrelli F, Garcia-Fuentes M, Mura P, Alonso MJ. A new drug nanocarrier consisting of chitosan and hydroxypropylcyclodextrin. Eur. J. Pharm. Biopharm. 63(2), 79-86 (2006). (Pubitemid 43792439)
82. Kwon TK, Kim JC. In vitro skin permeation of monoolein nanoparticles containing hydroxypropyl β-cyclodextrin/ minoxidil complex. Int. J. Pharm. 392(1), 268-273 (2010).
83. Gil ES, Li J, Xiao H, Lowe TL. Quaternary ammonium β-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier. Biomacromolecules 10(3), 505-516 (2009).
84. Gil ES, Wu L, Xu L, Lowe TL. β-cyclodextrin-poly (β-amino ester) nanoparticles for sustained drug delivery across the blood-brain barrier. Biomacromolecules 13(11), 3533-3541 (2012).
85. Skiba M, Skiba-Lahiani M, Arnaud P. Design of nanocapsules based on novel fluorophilic cyclodextrin derivatives and their potential role in oxygen delivery. J. Incl. Phenom. Macrocycl. Chem. 44(1-4), 151-154 (2002). (Pubitemid 38075681)
86. Cavalli R, Akhter AK, Bisazza A, Giustetto P, Trotta F, Vavia P. Nanosponge formulations as oxygen delivery systems. Int. J. Pharm. 402(1), 254-257 (2010).
87. Geze A, Chau LT, Choisnard L et al. Biodistribution of intravenously administered amphiphilic β-cyclodextrin nanospheres. Int. J. Pharm. 344(1), 135-142 (2007). (Pubitemid 47495983)
88. Memisoglu-Bilensoy E, Dogan AL, Hincal AA. Cytotoxic evaluation of injectable cyclodextrin nanoparticles. J. Pharm. Pharmacol. 58(5), 585-589 (2006).
89. El Fagui A, Dalmas F, Lorthioir C, Wintgens V, Volet G, Amiel C. Well-defined core-shells containing cyclodextrin in the shell: a comprehensive study. Polymer 52(17), 3752-3761 (2011).
90. Baek J-S, So J-W, Shin S-C, Cho C-W. Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system. Inter. J. Mol. Med. 30(4), 953-959 (2012).
91. Spada G, Gavini E, Cossu M, Rassu G, Giunchedi P. Solid lipid nanoparticles with and without hydroxypropyl-β-cyclodextrin: a comparative study of nanoparticles designed for colonic drug delivery. Nanotechnology 23(9), 095101 (2012).
92. Mariangela De Burgos MD, Tasic L, Fattori J et al. New formulation of an old drug in hypertension treatment: the sustained release of captopril from cyclodextrin nanoparticles. Inter. J. Nano. 6, 1005 (2011).